SLC5A2 and prostate cancer: This framework mimics an RCT by explicitly aligning patient eligibility, treatment initiation, and follow-up timing in the observational dataset, thereby reducing biases such as immortal time and selection bias. Through this approach, we aimed to generate clinically relevant evidence on the potential effects of SGLT2 inhibitors in men undergoing hormone therapy for prostate cancer.